Ackman to hold call to discuss investment in Valeant
By Amrutha Penumudi
(Reuters) - Pershing Square Holdings
Valeant shares have lost a quarter of their value since last Wednesday, following a report from influential short-seller Citron Research that suggested the Canadian drugmaker may have fraudulently inflated revenues by using its ties with a specialty pharmacy.
On Monday, the Valeant laid out a detailed defense of its relationship with the little-known specialty pharmacy Philidor Rx Services, but its arguments failed to calm all investor concerns.
Ackman, known for his brash bets, swept up 2.1 million additional shares last week even as Valeant shares plunged.
Pershing Square is set to hold the investor call on Oct. 30 at 9 am ET.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UK pledges additional £50 million to help contain Ebola outbreak in Congo
- Oil prices settle up more than $4 a barrel on renewed US-Iran fighting
- Oracle licensing practices on EU antitrust regulator's radar, source says
Create E-mail Alert Related Categories
ReutersRelated Entities
William Ackman, Pershing Square Capital, Citron Research, Hedge FundsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share